Overview

A Study of Nivolumab and Chemotherapy Followed by Surgery for Mesothelioma

Status:
Recruiting
Trial end date:
2023-11-01
Target enrollment:
Participant gender:
Summary
This study will test whether giving nivolumab in combination with pemetrexed and either cisplatin or carboplatin before surgery is a safe and effective approach to treating resectable mesothelioma without delaying surgery.
Phase:
Phase 1
Details
Lead Sponsor:
Memorial Sloan Kettering Cancer Center
Collaborator:
Bristol-Myers Squibb
Treatments:
Carboplatin
Cisplatin
Nivolumab
Pemetrexed